Clinical Trials Directory

Trials / Completed

CompletedNCT04588493

Secondary Lymphedema Due to Human Adjuvant Disease

Human Adjuvant Disease as a Cause of Secondary Lower Extremity Lymphedema

Status
Completed
Phase
Study type
Observational
Enrollment
5 (actual)
Sponsor
Hospital Angeles del Pedregal · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

This observational, descriptive, retrospective study the clinical and imaging findings of 10 lower legs of 5 patients with previous history of injection of modeling substances for cosmetic purposes at buttocks and hips ande developed lower limb edema. Lower limb lymphedema index and lymphoscintigraphy findings were evaluated and reported.

Detailed description

Lymphoscintigraphy findings were reported with the Transport index (TI), were any value over 5 will represent abnormalities in lymphatic function.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTLower extremity LymphoscintigraphyStudy of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points

Timeline

Start date
2017-03-01
Primary completion
2017-07-01
Completion
2017-12-01
First posted
2020-10-19
Last updated
2020-10-19

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT04588493. Inclusion in this directory is not an endorsement.